Brief: Reneo Pharmaceuticals To Present Data From Phase 1 REN001 Limb Immobilization Study At The 17Th International Congress On Neuromuscular Diseases (ICNMD 2022)
30/06/2022 13:04
June 30 (Reuters) - Reneo Pharmaceuticals Inc RPHM.O :
* RENEO PHARMACEUTICALS TO PRESENT DATA FROM PHASE 1 REN001
LIMB
IMMOBILIZATION STUDY AT THE 17TH INTERNATIONAL CONGRESS ON
NEUROMUSCULAR DISEASES (ICNMD 2022)
Source text for Eikon: ID:nGNXmJ64z
Further company coverage: RPHM.O
Recent news on Onkure Therapeutics
See all newsBrief: Onkure Therapeutics Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Onkure Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Onkure Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Onkure Therapeutics Inc expected to post a loss of $1.46 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-F5, Nextracker, Stryker